A Phase I, Single-Dose, Non-Randomised, Open-Label, Parallel-Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of balcinrenone in patients with mild and moderate hepatic impairment in comparison to a matched healthy control group.

开始日期2024-05-02

申办/合作机构

AstraZeneca PLC

NCT05884866

/ Recruiting临床2期IIT

Natriuretic-ureothelic Adaptation of Body Fluid Homeostasis During SGLT-2 Inhibition and/or Mineralocorticoid Receptor Modulation in Patients With Chronic Kidney Disease. A 4-arm, Double-blind, Double-dummy, Parallel-group, Phase 2 Study to Investigate the Mechanistic Effects of Dapagliflozin, Dapagliflozin + Balcinrenone, Balcinrenone and Placebo on Body Solute and Water Homeostasis and Energy Metabolism in Male and Female Participants Over 50 Years of Age With Chronic Kidney Disease.

The purpose of this study is to investigate the mechanistic effects of dapagliflozin 10 mg, alone or in combination with balcinrenone 150 mg, with balcinrenone 150 mg and placebo, on the way the body handles electrolytes and water content, as well as the effects these interventions may have on energy metabolism in participants with stage 3 chronic kidney disease.
The study interventions will be administered orally, daily, in addition to current therapy, for a duration of 28 days. This will allow us to maximize our ability to detect a drug effect while minimizing the drop-out rate that accompanies longer studies.
In order to understand the different mechanistic effects of these interventions on energy metabolism, the study will be conducted at two study sites. The study design and treatment allocation, treatment duration as well as sample analysis for evaluation of the primary endpoint will be identical for all participants, at both sites. Therefore, urine and plasma samples for analysis of water and electrolyte handling will be collected from all study participants at both sites.
In addition to the primary endpoint, the main study site (Nuremberg) will conduct a metabolic study to investigate the early- and late-effects of the interventions, while the second site, Marseille, will conduct an imaging sub-study to assess changes at the tissue level before and after treatment.

开始日期2023-07-13

申办/合作机构

Klinikum Nürnberg

NCT04595370

/ Completed临床2期

A Phase 2b, Randomised, Double-Blind, Active Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients With Heart Failure and Chronic Kidney Disease

The purpose of the study is to evaluate the efficacy and safety of AZD9977 in combination with dapagliflozin compared with dapagliflozin alone and to assess the dose-response relationship, dapagliflozin alone and 3 doses of AZD9977 combined with dapagliflozin on urinary albumin to creatinine ratio (UACR). The study will be conducted in participants with heart failure (HF) with left ventricular ejection fraction (LVEF [below 60%]) and chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR [between ≥ 20 and ≤ 60 mL/min/1.73 m^2, with at least 20% of participants with eGFR ≥ 20 to <30 mL/min/1.73^2 and a maximum of 35% of participants with eGFR ≥ 45 mL/min/1.73 m^2]).

开始日期2021-01-26

申办/合作机构

AstraZeneca PLC

100 项与 Balcinrenone 相关的临床结果

登录后查看更多信息

100 项与 Balcinrenone 相关的转化医学

登录后查看更多信息

100 项与 Balcinrenone 相关的专利（医药）

登录后查看更多信息

项与 Balcinrenone 相关的文献（医药）

2025-02-01·CPT-Pharmacometrics & Systems Pharmacology

Concentration–QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval

Article

作者: Rekic, Dinko ; Dota, Corina ; Ebrahimi, Ahmad ; Sundell, Jesper ; Parkinson, Joanna ; Johansson, Susanne ; Melin, Johanna

Abstract:

Balcinrenone (AZD9977) is a selective mineralocorticoid receptor modulator in development in combination with dapagliflozin for treatment of heart failure with impaired kidney function and chronic kidney disease. A prespecified concentration–QT analysis was performed based on data from a phase I single ascending dose study prospectively designed as a thorough QT study substitute. Oral single doses of balcinrenone of 5–800 mg, plus fractionated doses of 800 and 1200 mg, were evaluated in 62 healthy male participants. Time‐matched 12‐lead digital electrocardiogram and plasma concentrations were measured pre‐dose and up to 48 h postdose in the participants. Analysis was performed using a linear mixed‐effect model, where baseline‐adjusted Fridericia‐corrected QT interval (ΔQTcF) was a dependent variable and time‐matched balcinrenone concentration an independent variable. The model fit was deemed adequate by evaluation of goodness‐of‐fit plots, and the slope of the concentration–ΔQTcF relationship was nonsignificant (−0.003 ms/μmol/L; 95% confidence interval [CI]: −0.181, 0.176). The high clinical exposure scenario was defined as the maximum concentration (2.156 μmol/L) following the highest expected therapeutic dose (40 mg once daily) under fed conditions and in presence of a strong cytochrome P450 3A4 inhibitor. Estimated baseline‐adjusted and placebo‐corrected QTcF interval (ΔΔQTcF) at this concentration was 0.35 ms (90% CI: −1.29, 2.00). Furthermore, the upper 90% ΔΔQTcF CI was estimated to be below the threshold of regulatory concern of 10 ms at all observed concentrations (up to 16.7 μmol/L). Hence, it can be concluded that balcinrenone does not induce QTcF prolongation at the high clinical exposure scenario.

2025-02-01·EUROPEAN JOURNAL OF HEART FAILURE

Can the novel aldosterone inhibiting drug balcinrenone reduce hyperkalaemia and worsening renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure?

作者: Voors, Adriaan A. ; Heerspink, Hiddo J.L. ; Beldhuis, Iris E.

A review.Mineralocorticoid receptor antagonists (MRAs) are recommended for patients with HF with reduced ejection fraction (HFrEF) and may be considered for patients with a mildly reduced ejection fraction to reduce HF hospitalizations and improve survival.There is an important need for aldosterone inhibitors that have similar or better cardiac effects but less often cause hyperkalemia or WRF. In this issue of the journal, clin. data are presented of the novel selective mineralocorticoid receptor (MR) partial antagonist, balcinrenone (formerly AZD997).Thus novel aldosterone inhibiting drug balcinrenone reduce hyperkalemia and worsen renal function compared to steroidal mineralocorticoid receptor antagonists in heart failure.

2024-12-20·ORGANIC PROCESS RESEARCH & DEVELOPMENT

A Journey through Process Development Enhanced by Kinetic Modeling: An Efficient Manufacturing Route to Balcinrenone

作者: Cox, Robert J. ; Ronson, Thomas O. ; Pointon, Helen ; García-Morales, Cristina ; Neouchy, Zeina ; Page, Alice ; Dave, David ; Foulkes, Matthew J.

This work focuses on the accelerated development of a versatile process for synthesizing a key amide intermediate en route to the active pharmaceutical ingredient balcinrenone.The process development was facilitated by the implementation of predictive kinetic models at the early stages of development.The predictive kinetic models effectively guided and expedited route design, process design, and process optimization for both batch and continuous manufacturing of a telescoped asym. reduction/amidation process using methylamine in methanol.The implementation of the telescoped batch process led to significant enhancements in throughput, sustainability, and economic efficiency of the synthesis of balcinrenone, resulting in the successful manufacture of the key amide intermediate.Addnl., the utilization of a multilinear regression (MLR)-Kinetics hybrid model enabled the rapid development of an alternative process using methylamine in water, providing a contingency plan for manufacturing campaigns in the event of shortage of methylamine in methanol.In addition to the primary focus, this study expanded the application of kinetic modeling to guide process design and optimization for a second intermediate obtained via pH-controlled addition/cyclization, thereby enhancing understanding and throughput for this step.Finally, the use of a structured experimentation design involving initial kinetic studies led to the discovery of improved conditions for the final amide bond formation to produce balcinrenone.

项与 Balcinrenone 相关的新闻（医药）

2024-06-26

·FiercePharma

New CKD drugs are promising, but need stronger efficacy data, kidney docs say: GlobalData

In total, the chronic kidney disease market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Though a host of drugs currently under development are poised to massively expand the existing market for chronic kidney disease (CKD) treatments, they’ll need to go further to win the support of doctors, according to a new report. The segment is expected to expand at a compound annual growth rate of nearly 20% over the course of a decade, according to GlobalData’s estimates. The report comprises the seven major markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan, though GlobalData noted that the U.S. will be a disproportionately large contributor to that growth, thanks to its higher prevalence of CKD and costs of prescription medications. In total, the CKD market is forecast to balloon in size from $2.2 billion last year to $13.5 billion by 2033, during which time a range of new treatments are on track to make their debuts. Among those now in development are ProKidney’s cell therapy rilparencel, also known as React, and AstraZeneca’s combinations of zibotentan and dapagliflozin, and balcinrenone and dapagliflozin—all of which are currently in clinical trials. Meanwhile, Novo Nordisk is also exploring a potential expanded indication for Ozempic in CKD. Just last month, Novo shared results from its FLOW study of once-weekly Ozempic’s ability to reduce the risk of major kidney disease events in patients with both CKD and Type 2 diabetes. With a median follow-up period of nearly three and a half years, the study found that participants treated with the GLP-1 had an average 24% risk reduction compared to those assigned to the placebo group, and their rate of kidney function decline was “significantly slower.” Additionally, semaglutide was shown to reduce the risk of major cardiovascular events by 18% and all-cause mortality by 20%. Following that data drop, Novo confirmed that it will pursue expanded approvals for Ozempic in the U.S. and Europe by the end of this year. Despite the promising results from the studies of those and other potential new CKD therapeutics so far, according to GlobalData, many kidney doctors have yet to be convinced to shake up their existing CKD treatment standards and have “mixed views” about tacking on another drug to their patients’ current regimens. “It will be easier for new drug entrants to capture CKD market share if they offer a novel mechanism of action or help to improve compliance,” Kajal Jaddoo, senior pharma analyst at GlobalData, said in the report. “Overall, nephrologists surveyed by GlobalData have indicated that the pipeline for CKD is somewhat promising, but a significant improvement in efficacy would have to be demonstrated by any therapy for it to become either a replacement or add-on to the existing therapies.”

临床结果上市批准细胞疗法

2024-06-09

·医药观澜

10多款1类新药在中国获批临床，来自阿斯利康、信达生物、华东医药等公司

▎药明康德内容团队编辑根据中国国家药监局药品审评中心（CDE）官网数据，近两周有10多款1类新药首次获得临床试验默示许可。通过梳理，这些新药涵盖小分子新药、抗体偶联药物（ADC）、单抗、siRNA疗法等，它们拟用于治疗癌症、慢性肾病患者、化疗相关性腹泻、亨廷顿舞蹈病、痛风等。本文将对其中部分产品进行简要介绍，仅供读者参阅。图片来源：123RF 阿斯利康：balcinrenone/达格列净胶囊作用机制：盐皮质激素受体调节剂（MRM）+SGLT2抑制剂适应症：慢性肾病患者心力衰竭阿斯利康申报的balcinrenone达格列净胶囊获批临床，拟用于降低心力衰竭合并肾功能损害患者发生心力衰竭事件和心血管死亡的风险。根据阿斯利康官网资料，这是其正在开发的慢性肾病组合疗法中的一款，为盐皮质激素受体调节剂（MRM）+SGLT2抑制剂，目前在国际范围内处于3期临床研究阶段。达格列净为一款SGLT2抑制剂，已经获得美国FDA批准治疗慢性肾病（CKD）患者，阿斯利康正在临床试验中检验多种创新疗法与达格列净联用的效果，以求进一步改善CKD患者的治疗，其中balcinrenone与达格列净联用可能增强对CKD患者心力衰竭的治疗。艾伯维：budigalimab 作用机制：抗PD-1单抗适应症：肝细胞癌艾伯维申报的budigalimab获批临床，拟联合livmoniplimab治疗在一线免疫检查点抑制剂治疗后出现疾病进展的局部晚期或转移性Child-Pugh A级肝细胞癌（HCC）。根据艾伯维公开资料，ABBV-151（livmoniplimab）是其与argenx合作开发的GARP- TGF-β1人源化单克隆抗体抑制剂，正在开发用于治疗癌症；ABBV-181（budigalimab）是一种抗PD-1人源化单克隆抗体，正在开发用于与艾伯维其他分子联合治疗实体瘤和血液系统恶性肿瘤。在国际范围内，该联合疗法治疗肝癌和非小细胞肺癌处于2期临床研究阶段。汉康生技：HCB101注射液作用机制：SIRPα融合蛋白适应症：实体瘤和非霍奇金淋巴瘤根据汉康生技（HanchorBio）新闻稿，HCB101注射液是该公司管线中的第一个项目，为一个与IgG4-Fc连结、经过工程优化的SIRPα融合蛋白。它通过阻断巨噬细胞和癌细胞之间的“别吃我”信号来触发巨噬细胞的吞噬活性。研究表明，HCB101在癌细胞内及肿瘤微环境引发了明显不同的基因表现型态，表示其可能具有独特的作用机制。此前，该产品已经在美国和中国台湾地区获批临床，并自2023年4月开始开展全球多中心多地区临床试验。本次在中国获批临床，拟用于治疗晚期实体瘤及复发难治性非霍奇金淋巴瘤。派金生物：注射用重组酰化胰高血糖素样肽2类似物作用机制：GLP-2类似物适应症：化疗相关性腹泻根据派金生物新闻稿，本次获批临床的是一款重组酰化胰高血糖素样肽2（GLP-2）类似物，为一款长效重组多肽。研究表明，GLP-2类似物可以增加绒毛高度及隐窝深度，加强肠道上皮屏障，从而减轻局部炎症并改善肠道通透性，促进肠适应。派金生物新闻稿介绍，除了用于预防和治疗化疗严重腹泻外，在非临床试验中，该产品还被证明有开发成一周一次给药治疗短肠综合征、慢性肠炎等的临床价值。艾码生物：ER2001注射液作用机制：siRNA疗法适应症：早期显性亨廷顿舞蹈病根据艾码生物新闻稿介绍，ER2001注射液通过利用人体或动物体的自身器官组织作为生物反应器，在体内被“加工”成为活性形式的siRNA，并组装进入“生物反应器”同步产生的中枢神经系统靶向的内源外泌体中，经外泌体分泌“运输”到神经元细胞，可降解其中突变亨廷顿蛋白（mHTT）的mRNA，从而产生药效。该产品获批临床的适应症为早期显性亨廷顿舞蹈病（HD）。HD是一种遗传性神经系统变性病，临床表现为运动障碍、精神症状、认知障碍等。随着病程发展，疾病晚期表现为僵直、少动为主的帕金森症状，往往严重影响患者的生活质量和寿命。中美华东：注射用HDM2005 作用机制：靶向ROR1的ADC 适应症：晚期恶性肿瘤根据中美华东新闻稿介绍，注射用HDM2005是一款靶向ROR1的ADC，现有数据显示其具有良好的成药性和安全性。ROR1是一种典型的肿瘤胚胎蛋白，该靶点具有广谱抗肿瘤性，在多类肿瘤中高度表达，是潜力ADC靶点。HDM2005已经在临床前的药效学研究、药代动力学研究及安全性评价中展现出良好的抗肿瘤活性和安全性。该产品本次获批临床的适应症为晚期恶性肿瘤。加科思：JAB-30355片作用机制：p53 Y220C激活剂适应症：携带TP53 Y220C突变的晚期实体瘤 p53 Y220C突变是一种发生在p53的DNA结合域的常见突变，携带这一突变的p53难以维持稳定的DNA结合域构象，无法完成应有的DNA调控功能。JAB-30355正是加科思自主研发的一种口服生物活性小分子激活剂，拟开发用于治疗携带P53 Y220C突变的局部晚期或转移性实体瘤患者。信达生物：替古索司他片作用机制：XOI靶向小分子适应症：痛风信达生物申报的1类新药替古索司他片已经获得临床试验默示许可，拟开发治疗痛风。根据信达生物公开资料，替古索司他片（IBI128）是一款全新非嘌呤类似物——黄嘌呤氧化酶抑制剂（XOI）。信达生物于2022年12月与总部位于韩国的LG公司化学达成一项约9550万美元的合作，从而获得该产品在中国的开发和商业化权利。除了上述产品，近期还有其他1类新药获批临床，或获批针对新适应症开展临床研究，限于篇幅，此处不再一一赘述。希望这些1类新药后续临床研究进展顺利，早日取得突破，造福患者。参考资料： [1]中国国家药监局药品审评中心（CDE）官网.Retrieved June 8，2024, From https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c [2]各公司官网及公开资料本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

临床2期临床3期抗体药物偶联物siRNA

2023-05-05

·PRNewswire

Chronic Kidney Disease Competitive Landscape Report 2023: Comprehensive Insights About 75+ Companies and 95+ Drugs

DUBLIN, May 5, 2023 /PRNewswire/ -- The "Chronic Kidney Disease - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 95+ drugs in Chronic Kidney Disease Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In March 2023, POXEL SA, announced the publication of preclinical results in autosomal dominant polycystic kidney disease (ADPKD) for PXL770, a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. For the first time, POXEL SA showed beneficial effects of a direct and selective AMPK activator in preclinical ADPKD models from three species mouse, human, and dog. These results confirm the potential utility of AMPK activation for this disease and support the development of PXL770 in a Phase 2 clinical program for ADPKD. In February 2023, AstraZeneca announced the successful completion of the acquisition of CinCor Pharma, Inc. The acquisition bolsters AstraZeneca's cardiorenal pipeline by adding baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension, to its cardiorenal portfolio. In January 2023, The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance (empagliflozin) tablets, which is being investigated as a potential treatment to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company announced. In November 2022, The Medical Research Council Population Health Research Unit (MRC PHRU) at the University of Oxford, which designed, conducted and analyzed EMPA-KIDNEY in a scientific collaboration with Boehringer Ingelheim and Eli Lilly and Company, announced that EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% vs. placebo (HR; 0.72; 95% CI 0.64 to 0.82; P< 0.0001). In October 2022, Revelation Biosciences Inc. announced positive results in a preclinical model of acute kidney injury (AKI), chronic kidney disease (CKD). Treatment with REVTx-300 significantly reduced renal cortical fibrosis in a dose dependent manner in the medium and high dose groups (21.7% reduction (p < 0.05) and 29.3% (p < 0.05), respectively) and was comparable to a known TGF inhibitor of fibrosis used as a positive control (38.1% reduction (P < 0.05)). In October 2022, French Biopharma Company, Poxel SA announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to PXL770 for the treatment of patients with autosomal-dominant polycystic kidney disease (ADPKD). PXL770 is a novel, first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator - and is also a phase 2 ready ADPKD asset, subject to additional financing. In-depth Commercial Assessment: Chronic Kidney Disease Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Current Treatment Scenario and Emerging Therapies: How many companies are developing Chronic Kidney Disease drugs? How many Chronic Kidney Disease drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for Chronic Kidney Disease and their status? What are the key designations that have been granted to the emerging and approved drugs? Key Players Boehringer Ingelheim Eli Lilly and Company Reata Pharmaceuticals Novo Nordisk KBP Biosciences AstraZeneca Allena Pharmaceuticals SCOHIA PHARMA DiaMedica Therapeutics CinCor Pharma Galapagos NV Sentien Biotechnologies, Inc. Regeneron Pharmaceuticals UnicoCell Biomed OccuRx Pharmicell Lisata Therapeutics Unicycive Therapeutics Senda Biosciences Sarfez Pharmaceuticals Rege Nephro Orgenesis GNI Group Algomedix Maze Therapeutics Chinook Therapeutics Angion Biomedica Corp Arch Biopartners Scohia Pharma Algernon Pharmaceuticals TICEBA GmbH Key Products Empagliflozin Bardoxolone methyl Ziltivekimab KBP-5074 AZD9977 ALLN-346 BI-685509 SCO-792 DM199 Baxdrostat GLPG2737 SBI-101 REGN5459 ELIXCYTE FT011 Cellgram-CKD CLBS201 UNI-494 Research Program SZ007 Renal progenitor cells MSCKD F351 Research programme: TRPC6 antagonist APOL1 Programme Research and discovery programs: severe chronic kidney disease ROCK2 Inhibitor LSALT peptide SCO-116 Repirinast Polycystic kidney disease (PKD) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

临床结果并购临床2期临床3期孤儿药

100 项与 Balcinrenone 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15418

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性肾病	临床2期	美国	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	日本	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	比利时	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	保加利亚	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	加拿大	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	捷克	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	丹麦	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	德国	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	匈牙利	AstraZeneca PLC	2021-01-26
慢性肾病	临床2期	印度	AstraZeneca PLC	2021-01-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04595370 (MIRACLE, CTgov)	临床2期	心脏衰竭 \| 慢性肾病	153	Dapagliflozin	廠顧鏇淵壓蓋醖鹽膚壓(構鬱淵廠齋獵壓鹽餘壓) = 廠獵顧鏇齋壓糧壓願憲夢願獵觸醖蓋襯醖膚廠 (製壓壓襯鑰觸淵觸範範, 網網簾築艱鏇遞衊鏇廠 ~ 憲鹹鹹構鏇築製顧獵鹽) 更多	-	2024-11-19
NCT03682497 (Pubmed) 人工标引	临床1期	心脏衰竭 \| 肾功能不全	68	AZD9977	顧繭壓夢廠憲淵願窪繭(選糧繭積淵觸築憲襯淵) = 壓積範願構繭鏇膚襯築醖繭餘繭衊鑰鏇範繭醖 (鹽選醖範衊夢壓廠鹹簾, -5.3 ~ 4.4)	积极	2022-08-15
				spironolactone	顧繭壓夢廠憲淵願窪繭(選糧繭積淵觸築憲襯淵) = 觸廠衊廠鏇願鹹壓願簾醖繭餘繭衊鑰鏇範繭醖 (鹽選醖範衊夢壓廠鹹簾, -0.8 ~ 7.5)
NCT03435276 (Pubmed) 人工标引	临床1期	高钾血症	27	AZD9977	衊築淵遞餘繭積積壓憲(鏇窪醖網顧顧網範繭蓋) = 觸艱夢齋選鏇鹽選壓憲顧壓蓋壓醖廠選窪糧壓 (網壓憲餘襯簾廠鹹醖鑰 )	积极	2020-03-01
				Placebo	衊築淵遞餘繭積積壓憲(鏇窪醖網顧顧網範繭蓋) = 艱遞鬱醖鏇醖鬱衊築鏇顧壓蓋壓醖廠選窪糧壓 (網壓憲餘襯簾廠鹹醖鑰 )
NCT03682497 (ESC2019)	临床1期	射血分数保留型心力衰竭 \| 射血分数中等的心力衰竭	27	AZD9977	構蓋鹽顧壓膚齋築鹹鹹(願鑰觸壓鏇壓艱廠襯淵) = A total of 7 adverse events occurred in 4 participants (22.2%) receiving AZD9977 and 8 events occurred in 6 participants (66.7%) receiving placebo, none severe or resulting in withdrawal from the study 顧願構淵網築築衊壓鏇 (製遞淵艱糧獵醖夢鬱衊 )	-	2019-09-03
				Placebo